Back To TOP

Learn About Us

At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.

 

 

 

  • Last year, we helped more than 100,000* fully insured, underinsured and uninsured patients with access issues
  • Every year, we support privately insured patients through our co-pay card programs
  • We have supported co-pay assistance foundations with more than $932† million in donations since 2005
  • Since 1985, when its first product was approved, Genentech has donated $3.50‡ billion in free medicine through the Genentech® Access to Care Foundation (GATCF) and other product donation programs

 

ZELBORAF Access Solutions

ZELBORAF Access Solutions offers a full range of programs and services to meet the needs of patients and health care professionals. We provide what patients need for access, from benefits investigations through patient assistance options.Learn more

 

* Patients must meet certain criteria.
† Amount is approximate pending final financial audit confirmation; data published in March 2013.
‡ GATCF donation value is based on the most current forecast.

Watch the
Tutorial Video

FOR VIDEO POPUP CLICK HERE

FAQs

 
Q:

When should I refer my patient to ZELBORAF Access Solutions for help?

 
A: 

At any point after you have prescribed ZELBORAF® (vemurafenib), you can refer your patient to ZELBORAF Access Solutions. Learn more in See How We Can Help.

 

 

Q:

 

Can ZELBORAF Access Solutions assist with co-pay issues?

 
A: 

Yes. We can help with co-pay issues in two ways, for both privately and publicly insured patients. Learn more in Find Patient Assistance.

 

 

Q:

 

Is there assistance for uninsured patients who have been prescribed ZELBORAF?

 
A: 

Yes. The Genentech® Access to Care Foundation provides help for qualified patients. These include patients who are uninsured or whose health plans have denied payment for ZELBORAF. They must meet certain financial and medical requirements. Learn more in Help For Uninsured Patients.

 

 

Learn More About
ZELBORAF
  • LEARN about treatment with Zelboraf
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for ZELBORAF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information (Current Version)

ZELBORAF Indication and Important Safety Information

INDICATION

ZELBORAF™ (vemurafenib) is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test.

ZELBORAF is not recommended for use in patients with wild-type BRAF melanoma.

Important Safety Information

Cutaneous squamous cell carcinoma, serious hypersensitivity reactions including anaphylaxis, serious dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, QT prolongation, liver laboratory abnormalities, photosensitivity, ophthalmologic reactions, and new primary malignant melanoma have all been observed or associated with ZELBORAF treatment.

ZELBORAF may cause fetal harm when administered to a pregnant woman based on its mechanism of action.

Confirmation of BRAFV600E mutation-positive melanoma as detected by an FDA-approved test is required for selection of patients appropriate for ZELBORAF therapy. The efficacy and safety of ZELBORAF have not been studied in patients with wild-type BRAF melanoma.

The most common adverse reactions of any grade (≥30%) reported were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see accompanying full Prescribing Information for additional important safety information.